Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate

Oncology and immunology companies captured more than $3.9 billion, or over 40%, of the more than $9 billion raised by venture-backed biotechs in H1 2026, while the global oncology-drug market is projected to grow from $256.5 billion in 2025 to nearly $700 billion by 2034 (11.8% CAGR). The article highlights positive clinical and platform developments at Moderna, Amgen, Illumina, Iovance and Halozyme, and recommends diversified biotech ETF exposure to manage single-drug development risk. Recommended funds include FBT, up 29.8% YTD; BBH, up 23.8%; and BBP, up 29.9%, with expense ratios of 55bps, 35bps and 34bps, respectively.

Analysis

The investable implication is less broad oncology beta than a bifurcation between platform toll collectors and capital-intensive therapeutic developers. HALO can compound through partner nominations with limited commercial infrastructure, while ILMN benefits only if oncology research programs convert into recurring clinical-testing volumes; the latter remains exposed to hospital-capex budgets and MRD competition from NTRA and GH. IOVA has the highest operational leverage but also the weakest risk-adjusted profile: manufacturing capacity, treatment-center adoption and reimbursement can matter more than additional trial headlines.

The recent biotech ETF performance makes this a poor point to chase generic sector exposure. BBH is effectively a large-cap-biotech allocation with meaningful AMGN/MRNA concentration, while BBP's smaller asset base creates liquidity and rebalance-risk concerns in a risk-off tape. FBT offers cleaner diversification, but a broad oncology narrative will not protect it from rate-driven multiple compression; long-duration development assets remain highly sensitive to real yields over the next 1-3 months.

Consensus may be over-crediting oncology innovation to MRNA's standalone economics. The near-term value capture from combination regimens is likely greater for MRK, which controls the established checkpoint backbone and commercial channel, unless future data demonstrate a durable benefit sufficient to alter treatment sequencing. Over 6-18 months, the more durable second-order beneficiaries are diagnostics and drug-delivery firms that can participate across multiple winning molecules, but only where utilization—not research collaborations—appears in revenue guidance.

Key falsifiers: HALO partner-driven royalty or product-sales guidance below expectations; ILMN's clinical-sequencing revenue failing to outgrow core instrument demand; IOVA reporting weak treated-patient growth or rising cost per patient; and a sustained rise in real yields that reverses biotech fund flows. The article's venture-financing statistic is a sentiment indicator, not evidence of near-term public-company earnings conversion.

Key Decisions for Investors

• Initiate a 6-12 month long HALO / short XBI pair, sized beta-neutral: favor recurring platform economics over pre-revenue clinical-duration risk. Target 15-20% relative upside; exit if HALO's next guidance update does not show incremental partner-program monetization or if the pair underperforms by 10%.
• Accumulate MRK on market weakness over the next 1-3 months rather than chase MRNA: MRK retains the superior risk-adjusted exposure to successful combination-regimen adoption through its installed commercial franchise. Use a 12-month horizon; reassess if competing checkpoint regimens pressure Keytruda treatment duration or pricing.
• Avoid new IOVA exposure until quarterly treated-patient volume, gross margin and cash-burn data validate commercial scaling. Treat favorable clinical updates without evidence of center activation and reimbursement conversion as a sell-the-news risk.
• For diversified exposure, prefer FBT over BBP for liquidity and diversification, but enter only on a 5-8% biotech pullback or after real yields stabilize. Do not use BBH as a pure oncology vehicle given its large-cap concentration.
• Set an ILMN watch alert for evidence that MRD and oncology sequencing are driving consumables growth above the core business rate. If that disclosure emerges, revisit a 6-18 month long ILMN thesis; absent it, research partnerships alone are insufficient for an earnings upgrade.